Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay-Reference-Cited by-同舟云学术

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay

Published:2015-07-07 Issue:3 Volume:22 Page:560-566
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Prat Aleix,Galván Patricia,Jimenez Begoña,Buckingham Wesley,Jeiranian H. Arthur,Schaper Carl,Vidal Maria,Álvarez Martina,Díaz Sherley,Ellis Catherine,Nuciforo Paolo,Ferree Sean,Ribelles Nuria,Adamo Barbara,Ramón y Cajal Santiago,Peg Vicente,Alba Emilio

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response;Nature Communications;2024-07-11

2. Tailoring neoadjuvant systemic therapy in breast cancer: “The advent of a personalized approach”—The Breast‐Gynecological and Immuno‐Oncology International Cancer Conference (BGICC) consensus and recommendations;Cancer;2024-07-10

3. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis;Expert Review of Anticancer Therapy;2024-05-17

4. Basal–epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer;EMBO Molecular Medicine;2024-03-13

5. Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer;Cancer Treatment Reviews;2024-02